Chemoradiotherapy with Atezolizumab (Monoclonal Antibody) for Treating Bladder CancerResearch Question:
How well does chemotherapy and radiation therapy work with or without atezolizumab
in treating patients with localized muscle invasive bladder cancer?
Basic Study Information
Purpose:Location: University of Rochester Medical Center
This phase III trial studies how well chemotherapy and radiation therapy work with
or without atezolizumab in treating patients with localized muscle invasive bladder
cancer. Radiation therapy uses high energy rays to kill tumor cells and shrink tumors.
Drugs used in chemotherapy, such as gemcitabine, cisplatin, fluorouracil and mitomycin-C,
work in different ways to stop the growth of cancer cells, either by killing the cells,
by stopping them from dividing, or by stopping them from spreading. Giving chemotherapy
with radiation therapy may kill more tumor cells. Immunotherapy with monoclonal antibodies,
such as atezolizumab, may help the body's immune system attack the cancer, and may
interfere with the ability of tumor cells to grow and spread. Giving atezolizumab
with radiation therapy and chemotherapy may work better in treating patients with
localized muscle invasive bladder cancer compared to radiation therapy and chemotherapy
Study Reference #: RGUB19120
Lead Researcher (Principal Investigator)
Study Contact InformationStudy Coordinator: Liana Gonsalves
Phone: (585) 275-7848
Additional Study Details
Trial Not Found
The study you are looking for is not active at this time.
Return to Search